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Abstract
We report on 64 patients who did not achieve erections adequate for satisfactory sexual in-
tercourse from among a total of 243 patients who were prescribed PDE5 inhibitors for erectile
dysfunction (ED). Intracavernous injection (ICI) of PGE was performed in this non-responder
group. An ICI of 20 or 40 mcg of PGE1 in 1 ml saline was performed and the responses evaluated.
Forty-nine out of 64 (77 percent ) cases responded to 20 mcg of PGE1. Forty mcg of PGE was in-
jected into the 15 non-responding cases, and 9 patients responded favorably. The overall effective
rate was 58/64 (91 percent ). No major adverse effects were observed.
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We report on 64 patients who did not achieve erections adequate for satisfactory sexual intercourse from among a total of 243 patients who were prescribed PDE5 inhibitors for erectile dysfunction
(ED). Intracavernous injection (ICI)of PGE?was performed in this non-responder group. An ICI of 20 or 40 mcg of PGE?in 1 ml saline was performed and the responses evaluated. Forty-nine out of 64 (77 ) cases responded to 20 mcg of PGE?. Forty mcg of PGE?was injected into the 15 non-responding cases, and 9 patients responded favorably. The overall eﬀective rate was 58/64(91
). No major adverse eﬀects were observed.
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E rectile dysfunction (ED) is a not uncommon condition caused by psychiatric and physical disorders. Since their introduction, Phosophodiesterase 5 (PDE5) inhibitors have become the ﬁrst choice of treatment for ED, and have eﬃcacy rates of 68-79 ［1
-3］. However, there are still non-responders and contraindications for this oral therapy. The intracaver-
nous injection(ICI)of prostaglandin E?(PGE?)is a safe and eﬀective treatment option for such patients. The referred eﬀectiveness of ICI of PGE?is 68-88 ［4-6］.
A study of ICI of PGE?carried out in our institute is reported.
From March 1999 to March 2004, PDE5 inhibitors were prescribed to 243 ED patients in the outpatient clinic at the Okayama University Hospital. There were 64/243
(26 )cases in which PDE5 inhibitors were not eﬀective
 
in achieving erections adequate for satisfactory sexual intercourse. We performed ICI of PGE?in this group of 64 patients. Their ages were between 23 and 84(mean 54.5)years. ICI of 20 mcg of PGE?in 1 ml saline was performed and the response was evaluated 20 min later.
The therapeutic eﬀects were evaluated according to the criteria laid down by the International Society for Sexual and Impotence Research (ISSIR), and patients who obtained responses 2 and 3 were considered responders.
We performed ICI of 40 mcg of PGE?in the failed group of 15 cases.
Forty-nine patients responded to 20 mcg of PGE?and 9 patients needed 40 mcg. The over-all eﬀective rate was 58/64(91 ). Responses 2 and 3 were obtained in 21 and 37 cases respectively;no prolonged erection was observed. In the responder group, 10 had functional ED and 48 organic ED. In the ﬁnal non-responder group of 6 cases, all patients had organic ED, including 5 who were diabetic. No critical adverse eﬀects were observed in any of the patients.
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Shabsigh et al. reported success rates of 85.1-89.6 by intracavernous alprostadil alfadex in at-home therapy after sildenaﬁl failed, and the most common side eﬀect was penile pain in 29.4  of the patients［8］. In our study, ICI was performed by doctors in the out-patient clinic and not by self injection at home, but our results were similar to those of Shabsigh et al. PGE?therapy can be used eﬀectively and safely in patients who fail to respond to PDE5 inhibitors. At present in Japan, self ICI of PGE?is not permitted by the Ministry of Health,
Labour and Welfare. Therefore, a long-term evaluation of the eﬀects of ICI of PGE?, including self injection in Japan, is needed. Virag et al. described an eﬃcacy of 84.8  in an 8-year self-ICI study. There were no signiﬁcant diﬀerences in the results of ICI therapy for ED between other countries and Japan. Therefore, we con-
clude that this treatment can be successfully carried out in Japan.
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